Biotech | October 27, 2025
Novartis to acquire Avidity Biosciences for $12 billion
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walking
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
_256_384.jpg)
The council has also reduced the GST to 5 per cent on a few more Covid-19 medicines
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
